CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy.
Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T 细胞是有前景的肿瘤治疗手段,但因无法精确调控 T 细胞活化,其安全性和疗效仍面临挑战。本研究开发了一种 DNA 逻辑 CAR(DL-CAR)系统,可根据特定抗原组合模式实现可编程靶向并精确清除肿瘤。该系统以 HaloTag 作为胞外结构域用于 DNA 偶联,从而借助 DNA 逻辑计算控制肿瘤靶向适配体的组装,实现通用和组合式抗原识别。DL-CAR-T 细胞能够靶向表达不同抗原的肿瘤细胞,并通过 AND、OR 和 INHIBIT 布尔逻辑控制 CAR 回路,实现特异性 T 细胞活化和细胞杀伤。在小鼠模型中,DL-CAR 系统显示出较强的肿瘤清除能力;AND、OR 和 INHIBIT 门控计算均提高了其对特定抗原组合肿瘤的选择性。DL-CAR 有望为开发用于精准肿瘤治疗的可编程 CAR-T 回路提供新范式。
Chimeric antigen receptor (CAR) T cells, a promising cancer therapeutics, still face challenges in safety and efficacy due to the incapability to precisely regulate T cell activation.
Here we develop a DNA-logic CAR (DL-CAR) system that enables programmable targeting and precise ablation of tumors with specific antigen combination patterns. The DL-CAR system is engineered using HaloTag as an extracellular domain for DNA conjugation, which allows controlling the assembly of tumor-targeting aptamers for universal and combinatorial antigen recognition via DNA logic computation.
DL-CAR-T cells are shown to be capable of targeting tumor cells with different antigens and controlling the CAR circuit through AND, OR, and INHIBIT Boolean logic for specific T-cell activation and cytolysis. The DL-CAR system demonstrated high efficacy for tumor eradication in mouse models, with the AND-, OR-, and INHIBIT-gated computation affording enhanced selectivity for tumors with specific antigen combinations. DL-CAR may provide a new paradigm to develop programmable CAR-T circuits for precision cancer therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。